3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
18
Lung Neoplasms
8
Small Cell Lung Carcinoma
6
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Hepatocellular
4
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Cholangiocarcinoma
3
Triple Negative Breast Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Mouth Neoplasms
1
Liver Diseases
1
Laryngeal Neoplasms
1
Interventions
Specimen Handling
4
Biopsy
4
Magnetic Resonance Spectroscopy
3
Cyclophosphamide
3
sodium-iodide symporter
2
ruxolitinib
2
duvelisib
2
cemiplimab
2
X-Rays
2
Vincristine
2
Prednisone
2
Photons
2
Immunoglobulin G
2
Etoposide
2
Doxorubicin
2
Disulfides
2
prednylidene
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Peripheral Blood Stem Cell Transplantation
1
Oxaliplatin
1
Nivolumab
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell
×
durvalumab
×
30 days
×
Clear all
No trials found.